Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients

Blood

Volumn 122, Issue 11, 2013, Pages 1873-1880

  Geddings, Julia E ^a   Mackman, Nigel ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TISSUE FACTOR POSITIVE MICROPARTICLE; UNCLASSIFIED DRUG;

APOPTOSIS; BLOOD CLOTTING; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CENTRIFUGATION; COLORECTAL CANCER; COLORECTAL TUMOR; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; EXOSOME; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; INFERIOR CAVA VEIN; LIPOPROTEIN BLOOD LEVEL; LIVER CELL CARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; MULTIVESICULAR BODY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS TUMOR; PREDICTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; VEIN THROMBOSIS; ANIMAL; BIOLOGICAL MODEL; BLOOD; MEMBRANE MICROPARTICLE; METABOLISM; NEOPLASM; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ANIMALS; CELL-DERIVED MICROPARTICLES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RISK FACTORS; THROMBOPLASTIN; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84887361291     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-460139     Document Type: Review

References (98)

1. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007; 110(6):1723-1729.
2. Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest. 2012;122(7): 2331-2336.
3. Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 2011;106(2):371-378.
4. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634.
5. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-464.
6. Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4(3): 529-535.
7. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009;27(29):4839-4847.
8. Falanga A, Marchetti M, Russo L. Venous thromboembolism in the hematologic malignancies. Curr Opin Oncol. 2012;24(6): 702-710.
9. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
10. Cannegieter S. Epidemiology of cancer-associated thrombosis. Blood. In press.
11. Lee A. Treatment of cancer-related thrombosis. Blood. In press.
12. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(8):1687-1693.
13. Owens AP III, Mackman N. Tissue factor and thrombosis: The clot starts here. Thromb Haemost. 2010;104(3):432-439.
14. Vadivel K, Bajaj SP. Structural biology of factor VIIa/tissue factor initiated coagulation. Front Biosci. 2012;17:2476-2494.
15. Mackman N. The many faces of tissue factor. J Thromb Haemost. 2009;7(Suppl 1):136-139.
16. Osterud B, Bjorklid E. Tissue factor in blood cells and endothelial cells. Front Biosci (Elite Ed). 2012;4:289-299. [Elite Ed]
17. Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation: Which? Where? When? Arterioscler Thromb Vasc Biol. 2009;29(12):1989-1996.
18. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer. 1992;70(5): 1194-1201.
19. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg. 1995;82(8): 1101-1104.
20. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007; 13(10):2870-2875.
21. Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008;6(9):1517-1524.
22. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008; 10(5):619-624.
23. Dvorak HF, Quay SC, Orenstein NS, Dvorak AM, Hahn P, Bitzer AM, Carvalho AC. Tumor shedding and coagulation. Science. 1981;212(4497): 923-924.
24. Dvorak HF, Van DeWater L, Bitzer AM, et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res. 1983;43(9):4434-4442.
25. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-918.
26. Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol. 1974; 27(7):517-528.
27. Bovill EG, van der Vliet A. Venous valvular stasis-associated hypoxia and thrombosis: what is the link? Annu Rev Physiol. 2011;73:527-545.
28. Kumar DR, Hanlin E, Glurich I, Mazza JJ, Yale SH. Virchow's contribution to the understanding of thrombosis and cellular biology. Clin Med Res. 2010;8(3-4):168-172.
29. Moll S, Mackman N. Venous thromboembolism: a need for more public awareness and research into mechanisms. Arterioscler Thromb Vasc Biol. 2008;28(3):367-369.
30. Reitsma PH, Versteeg HH, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol. 2012;32(3):563-568.
31. Manly DA, Boles J, Mackman N. Role of tissue factor in venous thrombosis. Annu Rev Physiol. 2011;73:515-525.
32. Brooks EG, Trotman W, Wadsworth MP, et al. Valves of the deep venous system: an overlooked risk factor. Blood. 2009;114(6):1276-1279.
33. Diaz JA, Obi AT, Myers DD Jr, et al. Critical review of mouse models of venous thrombosis. Arterioscler Thromb Vasc Biol. 2012;32(3): 556-562.
34. Hampton AL, Diaz JA, Hawley AE, et al. Myeloid cell tissue factor does not contribute to venous thrombogenesis in an electrolytic injury model. Thromb Res. 2012;130(4):640-645.
35. von Bruhl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819-835.
36. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood. 2004;104(10):3190-3197.
37. Darbousset R, Thomas GM, Mezouar S, et al. Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood. 2012;120(10):2133-2143.
38. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005;105(1):192-198.
39. György B, Szabó TG, Pásztói M, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011; 68(16):2667-2688.
40. D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev. 2012;26(12): 1287-1299.
41. Garnier D, Magnus N, Lee TH, et al. Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. J Biol Chem. 2012;287(52): 43565-43572.
42. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost. 2009;101(3):439-451.
43. Owens AP III, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011; 108(10):1284-1297.
44. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol. 1967; 13(3):269-288.
45. Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, López JA. Microvesicleassociated tissue factor and Trousseau's syndrome. J Thromb Haemost. 2007;5(1):70-74.
46. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res. 2010;107(9): 1047-1057.
47. Ramacciotti E, Hawley AE, Wrobleski SK, et al. Proteomics of microparticles after deep venous thrombosis. Thromb Res. 2010;125(6): e269-e274.
48. Aleman MM, Gardiner C, Harrison P, Wolberg AS. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost. 2011;9(11):2251-2261.
49. Morrissey JH, Tajkhorshid E, Rienstra CM. Nanoscale studies of protein-membrane interactions in blood clotting. J Thromb Haemost. 2011;9(Suppl 1):162-167.
50. Key NS, Mackman N. Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Hemost. 2010; 36(8):865-875.
51. Thaler J, Ay C, Pabinger I. Clinical significance of circulating microparticles for venous thromboembolism in cancer patients. Hamostaseologie. 2012;32(2):127-131.
52. Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann KG. Immunologic quantitation of tissue factors. J Thromb Haemost. 2006;4(8): 1747-1755.
53. Wang JG, Geddings JE, Aleman MM, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood. 2012; 119(23):5543-5552.
54. Basavaraj MG, Olsen JO, Østerud B, Hansen JB. Differential ability of tissue factor antibody clones on detection of tissue factor in blood cells and microparticles. Thromb Res. 2012;130(3): 538-546.
55. Haubold K, Rink M, Spath B, et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost. 2009;101(6): 1147-1155.
56. Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008;6(11):1983-1985.
57. Wang JG, Manly D, Kirchhofer D, Pawlinski R, Mackman N. Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice. J Thromb Haemost. 2009; 7(7):1092-1098.
58. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticleassociated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5(3):520-527.
59. Lee RD, Barcel DA, Williams JC, et al. Preanalytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res. 2012;129(1): 80-85.
60. Thaler J, Ay C, Mackman N, et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost. 2012;10(7):1363-1370.
61. Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost. 2010;36(8):807-818.
62. Hron G, Kollars M, Weber H, et al. Tissue factorpositive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost. 2007; 97(1):119-123.
63. Campello E, Spiezia L, Radu CM, et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res. 2011; 127(5):473-477.
64. van Doormaal F, Kleinjan A, Berckmans RJ, et al. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost. 2012;108(1):160-165.
65. Zwicker JI. Impedance-based flow cytometry for the measurement of microparticles. Semin Thromb Hemost. 2010;36(8):819-823.
66. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15(22): 6830-6840.
67. Zwicker JI, Liebman HA, Bauer KA, et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013;160(4): 530-537.
68. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105(4): 1734-1741.
69. Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med. 2009;206(9): 1913-1927.
70. Brill A, Fuchs TA, Chauhan AK, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117(4):1400-1407.
71. Brill A, Fuchs TA, Savchenko AS, et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10(1):136-144.
72. Brill A, Yesilaltay A, De Meyer SF, et al. Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice. Arterioscler Thromb Vasc Biol. 2012;32(8):1841-1847.
73. Thomas GM, Brill A, Wagner DD. Cancer-Associated Thrombosis: Cancer Cell-Derived Microparticles as a Trigger of Venous Thrombosis in a Mouse Model of Flow Restriction. Blood (ASH Annual Meeting Abstracts). 2011;118:Abstract 34
74. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost. 2004;2(11):2065-2067.
75. Thaler J, Preusser M, Ay C, et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res. 2013;131(2):162-165.
76. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27(29): 4834-4838.
77. van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012;119(4):924-932.
78. Thaler J, Ay C, Mackman N, et al. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Invest. 2013;43(3):277-285.
79. Mukherjee SD, Swystun LL, Mackman N, Wang JG, Pond G, Levine MN, Liaw PC. Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients. Pathophysiol Haemost Thromb. 2010;37(2-4): 88-97.
80. Sartori MT, Della Puppa A, Ballin A, et al. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol. 2011; 104(1):225-231.
81. Sartori MT, Della Puppa A, Ballin A, et al. Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. Thromb Haemost. 2013;110:2.
82. Del Conde I, Shrimpton CN, Thiagarajan P, López JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106(5): 1604-1611.
83. Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000;96(1):170-175.
84. Sovershaev MA, Egorina EM, Osterud B, Hansen JB. Evidence for direct transfer of tissue factor from monocytes to platelets in whole blood. Blood Coagul Fibrinolysis. 2012;23(4):345-350.
85. Tilley RE, Holscher T, Belani R, Nieva J, Mackman N. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res. 2008;122(5): 604-609.
86. Boles JC, Williams JC, Hollingsworth RM, et al. Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity. Thromb Res. 2012;129(2):197-203.
87. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost. 2007;5(12): 2445-2452.
88. Fu Y, Zhou J, Li H, et al. Daunorubicin induces procoagulant activity of cultured endothelial cells through phosphatidylserine exposure and microparticles release. Thromb Haemost. 2010; 104(6):1235-1241.
89. Zhou J, Zheng Y, Shi J, et al. Daunorubicin induces procoagulant response through phosphatidylserine exposure in red blood cells. Thromb Res. 2010;125(2):178-183.
90. Zhou J, Shi J, Hou J, et al. Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia. J Thromb Haemost. 2010;8(4):773-782.
91. Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost. 2009; 7(8):1421-1423.
92. Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost. 2011;9(11): 2313-2321.
93. Manly DA, Wang J, Glover SL, Kasthuri R, Liebman HA, Key NS, Mackman N. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res. 2010;125(6):511-512.
94. Auwerda JJ, Yuana Y, Osanto S, de Maat MP, Sonneveld P, Bertina RM, Leebeek FW. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011;105(1): 14-20.
95. Cesarman-Maus G, Braggio E, Maldonado H, Fonseca R. Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. Leukemia. 2012;26(7): 1671-1674.
96. Rautou PE, Mackman N. Microvesicles as risk markers for venous thrombosis. Expert Rev Hematol. 2013;6(1):91-101.
97. Bharthuar A, Khorana AA, Hutson A, et al. Circulating microparticle tssue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res. Accepted.
98. Johnson GJ, Leis LA, Bach RR. Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty. Thromb Haemost. 2009;102(4):728-734.